--- title: Designing Research for Underrepresented Patient Populations description: Discover how inclusive trial design, co-creation, and empathy help researchers better serve underrepresented patient populations and achieve true health equity. image: https://blog.acclinate.com/hubfs/AdobeStock_1223859973%20(1).webp --- [![Acclinate Logo](https://blog.acclinate.com/hs-fs/hubfs/Acclinate-logo.png?width=2000&height=497&name=Acclinate-logo.png "Acclinate Logo")](https://www.acclinate.com/) - Products - [NOWINCLUDED](https://www.acclinate.com/products/nowincluded-the-community) - [eDICT](https://www.acclinate.com/products/e-dict) - Solutions - [Pharmaceutical Companies](https://www.acclinate.com/solutions/for-pharmaceutical-companies) - [Contract Research Organizations](https://www.acclinate.com/solutions/for-cros) - [Partners](https://www.acclinate.com/solutions/community-partners) - Company - [About Us](https://www.acclinate.com/about) - [Careers](https://www.acclinate.com/careers) - [News](https://news.acclinate.com) - Resources - [Resource Library](https://www.acclinate.com/resources) - [Blog](https://blog.acclinate.com) - [Press Kit](https://www.acclinate.com/press-kit) - [Events](https://www.acclinate.com/events) - [Glossary](https://www.acclinate.com/glossary) - [FAQ](https://www.acclinate.com/faq) - [Talk to Our Team](https://info.acclinate.com/get-in-touch) [![Talk to Our Team](https://no-cache.hubspot.com/cta/default/19943632/2e1c34dc-aaa1-43b8-b5f4-469b0db4e302.png)](https://cta-redirect.hubspot.com/cta/redirect/19943632/2e1c34dc-aaa1-43b8-b5f4-469b0db4e302) [![Acclinate Logo](https://blog.acclinate.com/hs-fs/hubfs/Acclinate_Logo.png?width=500&height=149&name=Acclinate_Logo.png "Acclinate Logo")](https://www.acclinate.com/) - Products - [**NOWINCLUDED**Acclinate’s B2C community platform ](https://www.acclinate.com/products/nowincluded-the-community) - [**e-DICT**Acclinate’s patented AI-powered technology ](https://www.acclinate.com/products/e-dict) - Solutions - [**Pharmaceutical Companies**Community-driven recruitment and real-world insights to support diverse, compliant clinical trials. ](https://www.acclinate.com/solutions/for-pharmaceutical-companies) - [**Contract Research Organization (CRO)**Scalable patient engagement and recruitment solutions that reduce risk and improve enrollment timelines. ](https://www.acclinate.com/solutions/for-cros) - [**Partners**Trusted partnerships that connect research opportunities with the communities they aim to serve. ](https://www.acclinate.com/solutions/community-partners) - Company - [**About us**We help clinical research teams reach diverse communities, build trust, and improve trial participation. ](https://www.acclinate.com/about) - [**Careers**Join a mission-driven team advancing inclusive clinical research and community-powered health innovation. ](https://www.acclinate.com/careers) - Resources - [**Resources Hub** ](https://www.acclinate.com/resources) - [**Glossary** ](https://www.acclinate.com/glossary) - [**Press Kit** ](https://www.acclinate.com/press-kit) - [**Events** ](https://www.acclinate.com/events) - [**Blog** ](https://blog.acclinate.com/) - [**News** ](https://news.acclinate.com/) - [![](https://cdn.prod.website-files.com/695fbca039298e2117988a78/69e7b588548c7ad7bd8ab0bc_9dd915489696393dc63d7785ee2e52c7_Question%20mark%20image.png) **FAQs** ](https://www.acclinate.com/faq) - [ Contact Us ](https://www.acclinate.com/contact-us) Stay up to date Get news directly in your inbox Topic All - [Affective Trust ](https://blog.acclinate.com/tag/affective-trust) - [Announcement ](https://blog.acclinate.com/tag/announcement) - [Clinical Research Software ](https://blog.acclinate.com/tag/clinical-research-software) - [Clinical Trial Recruitment Strategies ](https://blog.acclinate.com/tag/clinical-trial-recruitment-strategies) - [Community ](https://blog.acclinate.com/tag/community) - [Diversity in Clinical Trials ](https://blog.acclinate.com/tag/diversity-in-clinical-trials) - [e-DICT™ ](https://blog.acclinate.com/tag/e-dict) - [FDA Diversity Plan ](https://blog.acclinate.com/tag/fda-diversity-plan) - [FDA Guidance: Diversity in Clinical Trials ](https://blog.acclinate.com/tag/fda-guidance-diversity-in-clinical-trials) - [Health Equity ](https://blog.acclinate.com/tag/health-equity) - [Partnerships ](https://blog.acclinate.com/tag/partnerships) - [Representation in Healthcare ](https://blog.acclinate.com/tag/representation-in-healthcare) [Representation in Healthcare](https://blog.acclinate.com/topic/representation-in-healthcare) # Designing Research for Underrepresented Patient Populations Discover how inclusive trial design, co-creation, and empathy help researchers better serve underrepresented patient populations and achieve true health equity. ![Designing Research for Underrepresented Patient Populations](https://blog.acclinate.com/hubfs/AdobeStock_1223859973%20(1).webp) Clinical Trial Diversity: What Does It Really Mean? Clinical trials are critical for evaluating the safety and effectiveness of medical devices and pharmaceutical products. The results of trials guide t... Read More ![ Acclinate](https://blog.acclinate.com/hubfs/69b96486c4b036c19f462c19_acclinate-logo.png) [Acclinate](https://blog.acclinate.com/author/acclinate) Acclinate turns trust and data into better representation. Share this Post: [**](https://www.facebook.com/sharer/sharer.php?u=https://blog.acclinate.com/designing-research-for-underrepresented-patient-populations) [**](https://twitter.com/home?status=https://blog.acclinate.com/designing-research-for-underrepresented-patient-populations) [** ](https://www.linkedin.com/shareArticle?mini=true&url=https://blog.acclinate.com/designing-research-for-underrepresented-patient-populations&title=Designing%20Research%20for%20Underrepresented%20Patient%20Populations) Stay up to date Get news directly in your inbox ## Key Takeaways - Inclusive research design starts with intentionality—diversity doesn’t happen by accident. - Co-creating studies with community leaders builds trust, accessibility, and cultural relevance. - Flexible, participant-centered trial formats make research more inclusive for underrepresented patient populations. - Get on the path to more inclusive clinical research with our [comprehensive guide to advancing health equity](https://info.acclinate.com/advancing-health-equity-with-affective-trust-acclinate?hsCtaAttrib=195461305101). Historically, most clinical trials haven’t been built with underrepresented people in mind—and that shows in the data. For decades, systemic barriers have limited who participates in studies, which means findings haven't always reflected the full diversity of real-world populations. The damage this gap between study results and lived experience has caused is two-fold: entire communities have been excluded from health advancements, while the future of medical research has been stifled by siloed data. Let's explore how inclusive design, co-creation with community leaders, and flexible trial formats can better support underrepresented patient populations and clinical studies—and how Acclinate is helping reshape research around the people it has historically overlooked. ## Why Research Has Historically Overlooked Underrepresented Patient Populations Traditional research methods often exclude people unintentionally through strict eligibility criteria, site locations, or study designs that don’t consider cultural or logistical barriers. Eligibility requirements can screen out older adults, individuals with comorbidities, or those living far from research centers. Meanwhile, complex protocols, rigid visit schedules, and mistrust rooted in past abuses all contribute to low participation among marginalized communities. The result is a body of research that, while rigorous, often fails to represent the full human picture. Data gaps translate into treatment gaps, which perpetuate inequities. As the [National Institutes of Health](https://www.ncbi.nlm.nih.gov/books/NBK584396/?utm_source=chatgpt.com) notes, diverse participation is essential to ensure that medical advances benefit everyone—not just those easiest to reach. ## Principles of Inclusive Trial Design Designing for inclusion begins long before recruitment starts. It requires a shift from “How do we get people to join?” to “How can we design research that welcomes everyone in the first place?” ### 1. Inclusive Eligibility and Representation Trials should reflect the complexity of real-world patients. Rather than narrowing eligibility to the “ideal participant,” researchers can adapt criteria to include diverse ages, comorbidities, and social contexts. Expanding eligibility improves both representation and external validity. ### 2. Co-Creation With Community Leaders True inclusion requires collaboration. Partnering with community leaders, faith organizations, and advocacy groups ensures that research reflects the needs, values, and voices of the populations it aims to serve. This co-creation approach moves beyond token consultation—it gives communities agency in shaping study design, outreach, and communication. ### 3. Flexible, Participant-Centered Trial Formats Rigid, site-based studies can exclude those who face transportation, childcare, or work challenges. Hybrid and decentralized models—combining in-person and remote elements—allow participants to engage on their terms. These approaches expand access while maintaining data integrity. ### 4. Cultural Responsiveness and Empathy Inclusive design also means designing with empathy. Materials should be linguistically and culturally relevant, recruitment should acknowledge historical mistrust, and data use should be transparent. As Acclinate UX designer Apurva Chinta wrote in [Designing for Empathy: Creating Accessible Tech with a Human Touch](https://blog.acclinate.com/designing-for-empathy-creating-accessible-tech-with-a-human-touch), technology and research alike must “meet people where they are” to foster genuine connection. ### 5. Continuous Feedback and Accountability Diversity isn’t simply a goal, but a commitment to measure and improve over time. Building feedback loops into studies ensures ongoing communication and accountability, showing participants how their involvement shapes outcomes. [![Download Now – Before You Recruit: The Ultimate Guide to Advancing Health Equity in Clinical Trials](https://no-cache.hubspot.com/cta/default/19943632/interactive-188916301454.png) ](https://blog.acclinate.com/hs/cta/wi/redirect?encryptedPayload=AVxigLJ%2BJIWWyb%2FqtfCsZoW1tlkho%2ByFdm5RnaUPRkVXxdViJkCenhdbdwJz9CBnsbWXz6vutXNsSfzT4hedgP8MD8qAn5I1jG%2FP2IOld%2FS3io3qIWP2Cukp%2FgNHig%2FrEVFL33LYJRmkiM%2Fzlfzd2fVnm%2BA%2FwQ2V8RYRDLRhsD82vX19zheyVqnEx6GrxkJ7l22iBY4jbJyc5a5%2Be%2BFUqnGkN4bpCZoIQ7F8jquNZ7y7EPr1LYpqHjUhj6xzLYpjB8ZsVA%3D%3D&webInteractiveContentId=188916301454&portalId=19943632) ## How Acclinate Helps Reshape Research Around People Historically Overlooked At Acclinate, inclusion is built into our design philosophy. Our approach integrates data, systems, and human connection: - **Co-Design with communities:** We collaborate with local organizations and trusted messengers to create outreach materials, educational resources, and retention strategies that resonate with specific populations. - **Data-driven representation:** Through e-DICT™ analytics, we identify underrepresented patient populations, uncover enrollment gaps, and guide site selection for better demographic balance. - **Trusted engagement channels:** Our NOWINCLUDED community platform connects more than 170,000 members who share experiences, access trusted health information, and engage in research opportunities with transparency and respect. - **Culturally grounded practices:** Every touchpoint—from consent forms to digital messaging—is built to honor the lived experiences of diverse participants. This model advances inclusion from aspiration to action, helping sponsors design studies that reflect the people most impacted by their outcomes. ## The Business and Scientific Case for Inclusive Research Inclusive research design isn’t just ethical—it’s practical. Studies that include diverse populations produce data that’s more reliable, generalizable, and market-ready. Sponsors benefit from faster enrollment, fewer protocol deviations, and improved retention rates when trials align with participants’ realities. Regulatory bodies are taking note: the FDA now requires Diversity Action Plans outlining how sponsors will recruit and retain participants from underrepresented groups. Meeting these expectations means embedding inclusion into design, not adding it at the end. Ultimately, inclusive design delivers better science. When more people see themselves represented in research, trust grows, engagement increases, and healthcare outcomes improve for everyone. ## Moving From Design to Practice To operationalize inclusive design: - **Review your current protocols.** Identify eligibility or logistical barriers that may exclude certain groups. - **Engage communities early.** Build partnerships before protocol finalization, not after. - **Leverage hybrid models.** Integrate telehealth, mobile units, or remote monitoring to expand reach. - **Track inclusion metrics.** Use demographic data to monitor progress and course-correct as needed. - **Invest in empathy.** Train research teams to understand cultural nuance and communicate with transparency. These actions help transform research from an extractive process to a collaborative one—rooted in respect, trust, and shared benefit. ## The Future of Research Is Inclusive by Design The path to equity starts long before recruitment—it begins at the design table. By involving communities early, embedding empathy into every touchpoint, and embracing flexible trial models, we can create a research ecosystem that truly reflects the diversity of the world it seeks to serve. At Acclinate, we’re committed to helping sponsors lead that change—so every discovery moves us closer to a future where research represents all of us. **Want a closer look at how we approach inclusive research? [Schedule a 1:1 with our team.](https://blog.acclinate.com/cs/c/?cta_guid=55107ccc-ffdc-40cd-9072-0f0f1408baae&signature=AAH58kFyrYx8ysL09VOXMSmIfgPAmXWXeg&utm_referrer=https%3A%2F%2Fblog.acclinate.com%2Ftrust-is-a-two-way-street-building-health-equity-through-community-first-engagement&portal_id=19943632&pageId=153327030564&placement_guid=2e1c34dc-aaa1-43b8-b5f4-469b0db4e302&click=282ed6fc-8c10-42e5-9093-9225a75450a0&redirect_url=APefjpH85ahoDNN7rojqFE8_i333x-_h0JTStg9v4OwbONQ6bLHOl3s3lmejWzuCmPc6t4xPuwHORrA3LMY57FksIYEbK1dpvnqLN5psfTYqnKvuGNDsHpYHVa8x-dMFSPjSvwIbZqxY10pOEldt-N-QHzvMWeZ7gwERBa9POktgCwA3dXtsH2oRzyC9IItrARz8FsBjUeIpy-m6ZZODYP66B4D_eJ_nKfPvYcSxIsBOZUGJYeAiGug&hsutk=af2d6b60f434b25264f6c24b1b4bd070&canon=https%3A%2F%2Fblog.acclinate.com%2F&ts=1762136705325&__hstc=268225873.af2d6b60f434b25264f6c24b1b4bd070.1751404298255.1762132976783.1762136706307.47&__hssc=268225873.1.1762136706307&__hsfp=4113775001&contentType=listing-page)** **[![Before You Recruit: The Ultimate Guide to Advancing Health Equity in Clinical Trials](https://no-cache.hubspot.com/cta/default/19943632/77a48b61-8ce6-44a3-b69b-3d080ed93db6.png)](https://cta-redirect.hubspot.com/cta/redirect/19943632/77a48b61-8ce6-44a3-b69b-3d080ed93db6)** ## Recent Posts [![Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World](https://blog.acclinate.com/hubfs/mature-female-patient-at-doctors-appointment-2026-01-08-06-10-47-utc.webp) ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) [ Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) June 25, 2026 3 Min Read Drug development economics are changing. Sponsors are increasingly relying on a single pivotal trial to support approval. Though the goal of this appr... Read More [![Clinical Trial Generalizability: What Regulators Will Scrutinize Next](https://blog.acclinate.com/hubfs/woman-visiting-dermatologist-2026-01-08-22-23-31-utc.webp) ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) [ Clinical Trial Generalizability: What Regulators Will Scrutinize Next ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) June 25, 2026 3 Min Read For years, generalizability was framed as a methodological concern. Reviewers debated whether results could reasonably extend beyond a trial’s enrolle... Read More [![Site Engagement Index (SEI): Measuring What Actually Builds Trust](https://blog.acclinate.com/hubfs/computer-screen-trading-and-back-with-charts-hom-2026-01-09-09-28-19-utc.webp) ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) [- [Clinical Research Software](https://blog.acclinate.com/news/tag/clinical-research-software) ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) [ Site Engagement Index (SEI): Measuring What Actually Builds Trust ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) June 25, 2026 3 Min Read Clinical research lacks anything but metrics. Enrollment targets, site activation timelines, and digital engagement rates are tracked closely across s... Read More [![](https://blog.acclinate.com/hubfs/Imported_Blog_Media/6567a9f90c0cf111067913e2_Merck%20Pop%20Up2.png) ](https://blog.acclinate.com/acclinate-collaborates-with-merck-to-increase-clinical-trial-diversity) [ Acclinate to support Merck's oncology clinical trials ](https://blog.acclinate.com/acclinate-collaborates-with-merck-to-increase-clinical-trial-diversity) June 24, 2026 1 Min Read Acclinate, an expert in health equity through inclusive research, is collaborating with Merck, known as MSD outside the United States and Canada, to h... Read More [![Why Trial Diversity Is Now a Risk Management Strategy](https://blog.acclinate.com/hubfs/Why-Trial-Diversity-Is-Now-a-Risk-Management-Strategy.jpg) ](https://blog.acclinate.com/why-trial-diversity-is-now-a-risk-management-strategy) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/why-trial-diversity-is-now-a-risk-management-strategy) [ The New Control Lever: Why Trial Diversity Is Now a Risk Management Strategy ](https://blog.acclinate.com/why-trial-diversity-is-now-a-risk-management-strategy) March 2, 2026 3 Min Read For years, conversations around trial diversity were framed as ethical or reputational concerns. That framing no longer reflects regulatory reality. Read More [![Acclinate’s NOWINCLUDED: Turning Community Insights Into Research Equity](https://blog.acclinate.com/hubfs/AdobeStock_470269560.webp) ](https://blog.acclinate.com/acclinates-nowincluded-turning-community-insights-into-research-equity) [- [Community](https://blog.acclinate.com/news/tag/community) ](https://blog.acclinate.com/acclinates-nowincluded-turning-community-insights-into-research-equity) [ Acclinate’s NOWINCLUDED: Turning Community Insights Into Research Equity ](https://blog.acclinate.com/acclinates-nowincluded-turning-community-insights-into-research-equity) February 16, 2026 3 Min Read Clinical research equity efforts originate with good intentions. But they often hit a roadblock in practice: communities are asked to participate in h... Read More [![How Acclinate’s e-DICT™ Technology Builds Real-Time Community Trust](https://blog.acclinate.com/hubfs/AdobeStock_1631551849.webp) ](https://blog.acclinate.com/how-acclinates-e-dict-technology-builds-real-time-community-trust) [- [Community](https://blog.acclinate.com/news/tag/community) ](https://blog.acclinate.com/how-acclinates-e-dict-technology-builds-real-time-community-trust) [ How Acclinate’s e-DICT™ Technology Builds Real-Time Community Trust ](https://blog.acclinate.com/how-acclinates-e-dict-technology-builds-real-time-community-trust) February 9, 2026 3 Min Read Reaching underrepresented communities in healthcare research has never been simple. Participation decisions are shaped by lived experience, historical... Read More [![Data-Driven Inclusion](https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/Acclinate-Data-Driven-Inclusion.jpg) ](https://blog.acclinate.com/data-driven-inclusion-predictive-analytics-for-trial-enrollment) [- [Clinical Research Software](https://blog.acclinate.com/news/tag/clinical-research-software) ](https://blog.acclinate.com/data-driven-inclusion-predictive-analytics-for-trial-enrollment) [ Data-Driven Inclusion: Predictive Analytics for Trial Enrollment ](https://blog.acclinate.com/data-driven-inclusion-predictive-analytics-for-trial-enrollment) February 2, 2026 2 Min Read Subpar enrollment remains one of the most common causes of trial delays. But sponsors often miss a key factor: underrepresentation. Lack of diversity ... Read More [![Exploring Diversity in Clinical Research With Acclinate](https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/Exploring-Diversity-in-Clinical-Research-With-Acclinate.jpg) ](https://blog.acclinate.com/exploring-diversity-in-clinical-research-with-acclinate) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/exploring-diversity-in-clinical-research-with-acclinate) [ Exploring Diversity in Clinical Research With Acclinate ](https://blog.acclinate.com/exploring-diversity-in-clinical-research-with-acclinate) January 26, 2026 3 Min Read Diversity in clinical research remains a widely discussed goal, yet progress has been uneven. Trials still grapple with subpar representation, limited... Read More [![Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World](https://blog.acclinate.com/hubfs/mature-female-patient-at-doctors-appointment-2026-01-08-06-10-47-utc.webp) June 25, 2026 Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World Read More ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) [![Clinical Trial Generalizability: What Regulators Will Scrutinize Next](https://blog.acclinate.com/hubfs/woman-visiting-dermatologist-2026-01-08-22-23-31-utc.webp) June 25, 2026 Clinical Trial Generalizability: What Regulators Will Scrutinize Next Read More ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) [![Site Engagement Index (SEI): Measuring What Actually Builds Trust](https://blog.acclinate.com/hubfs/computer-screen-trading-and-back-with-charts-hom-2026-01-09-09-28-19-utc.webp) June 25, 2026 Site Engagement Index (SEI): Measuring What Actually Builds Trust Read More ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) ![Woman wearing Acclinate Shirt](https://blog.acclinate.com/hs-fs/hubfs/layer1_image.webp?width=1600&height=1068&name=layer1_image.webp) ![Medical Research Software e-DICT](https://blog.acclinate.com/hs-fs/hubfs/layer2_image.webp?width=885&height=885&name=layer2_image.webp) ![layer2.2_image](https://blog.acclinate.com/hs-fs/hubfs/layer2.2_image.webp?width=1505&height=1197&name=layer2.2_image.webp) ![layer3_image](https://blog.acclinate.com/hs-fs/hubfs/layer3_image.webp?width=1600&height=1067&name=layer3_image.webp) ## Ready to Measure Your True Impact? Partner with Acclinate to turn mission into measurable, data-driven action. [ Get Started ](https://www.acclinate.com/contact-us) [![Acclinate Logo Reversed](https://blog.acclinate.com/hs-fs/hubfs/footer_logo.png?width=1600&height=398&name=footer_logo.png "Acclinate Logo Reversed")](https://www.acclinate.com/) - Products - [NOWINCLUDED](https://www.acclinate.com/products/nowincluded-the-community) - [e-DICT](https://www.acclinate.com/products/e-dict) - Solutions - [Pharmaceutical Companies](https://www.acclinate.com/solutions/for-pharmaceutical-companies) - [CROs](https://www.acclinate.com/solutions/for-cros) - [Community Partners](https://www.acclinate.com/solutions/community-partners) - Resources - [Resources Hub](https://www.acclinate.com/resources) - [Glossary](https://www.acclinate.com/glossary) - [Press Kit](https://www.acclinate.com/press-kit) - [Events](https://www.acclinate.com/events) - [News](https://news.acclinate.com/) - [Blog](https://blog.acclinate.com/) - [FAQs](https://www.acclinate.com/faq) - Company - [About us](https://www.acclinate.com/about) - [Careers](https://www.acclinate.com/careers) - [Contact Us](https://www.acclinate.com/contact-us) - Follow Us - [** Linkedin](https://www.linkedin.com/company/acclinateinc/) - [Privacy Policy](https://www.acclinate.com/privacy) - [Terms of Service](https://www.acclinate.com/terms-of-use-acclinate) ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Acclinate", "url" : "https://blog.acclinate.com/author/acclinate" }, "dateModified" : "2026-05-08T14:06:16.164Z", "datePublished" : "2025-12-31T14:15:00.000Z", "headline" : "Designing Research for Underrepresented Patient Populations", "image" : [ "https://blog.acclinate.com/hubfs/AdobeStock_1223859973%20(1).webp" ], "mainEntityOfPage" : { "@id" : "https://blog.acclinate.com/designing-research-for-underrepresented-patient-populations", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://blog.acclinate.com/hubfs/Acclinate-logo.png" }, "name" : "Acclinate" } } ```